Click here to get full coverage on Early voting opens in Houston’s At-Large 4 and HCC District II runoffs - Houston Chronicle

Early voting opens in Houston’s At-Large 4 and HCC District II runoffs  Houston Chronicle

Early voting opens in Houston’s At-Large 4 and HCC District II runoffs - Houston Chronicle

Click here to get full coverage on HCC shares jump over 14% as board approves Rs 1,000 crore rights issue; record date & other details - MSN

HCC shares jump over 14% as board approves Rs 1,000 crore rights issue; record date & other details  MSN

HCC shares jump over 14% as board approves Rs 1,000 crore rights issue; record date & other details - MSN

Click here to get full coverage on HCC ₹1,000 Crore Rights Issue: Check entitlement, record date, other details here - CNBC TV18

HCC ₹1,000 Crore Rights Issue: Check entitlement, record date, other details here  CNBC TV18

HCC ₹1,000 Crore Rights Issue: Check entitlement, record date, other details here - CNBC TV18

Click here to get full coverage on Nabil Elhadi Omar: Evidence-Based Approaches to Reduce Financial Toxicity in HCC Treatment - Oncodaily

Nabil Elhadi Omar: Evidence-Based Approaches to Reduce Financial Toxicity in HCC Treatment  Oncodaily

Nabil Elhadi Omar: Evidence-Based Approaches to Reduce Financial Toxicity in HCC Treatment - Oncodaily

Click here to get full coverage on Study Identifies Role of EMP1+ Hepatic Stellate Cells in Liver Fibrosis and Hepatocellular Carcinoma Progression - geneonline.com

Study Identifies Role of EMP1+ Hepatic Stellate Cells in Liver Fibrosis and Hepatocellular Carcinoma Progression  geneonline.com

Study Identifies Role of EMP1+ Hepatic Stellate Cells in Liver Fibrosis and Hepatocellular Carcinoma Progression - geneonline.com

Click here to get full coverage on Glypican-3 (GPC3) Targeted Therapy Competitor Analysis Report 2025 - ResearchAndMarkets.com - The AI Journal

Glypican-3 (GPC3) Targeted Therapy Competitor Analysis Report 2025 - ResearchAndMarkets.com  The AI Journal

Glypican-3 (GPC3) Targeted Therapy Competitor Analysis Report 2025 - ResearchAndMarkets.com - The AI Journal

Click here to get full coverage on Integrative genomics characterizes HCC eRNAs for prognosis and targeted therapy - Nature

Integrative genomics characterizes HCC eRNAs for prognosis and targeted therapy  Nature

Integrative genomics characterizes HCC eRNAs for prognosis and targeted therapy - Nature

Click here to get full coverage on Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC - OncLive

Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC  OncLive

Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC - OncLive

Click here to get full coverage on Statewide push for adult education includes big boost for HCC - MassLive

Statewide push for adult education includes big boost for HCC  MassLive

Statewide push for adult education includes big boost for HCC - MassLive

Click here to get full coverage on Ether-Lipids Fuel Hepatocellular Carcinoma via PPARα Deficiency - Bioengineer.org

Ether-Lipids Fuel Hepatocellular Carcinoma via PPARα Deficiency  Bioengineer.org

Ether-Lipids Fuel Hepatocellular Carcinoma via PPARα Deficiency - Bioengineer.org

Click here to get full coverage on From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma - ASCO Daily News

From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma  ASCO Daily News

From Sorafenib to Precision Medicine: The Future of Systemic Therapy in Hepatocellular Carcinoma - ASCO Daily News

Click here to get full coverage on Mayo Clinic uses investigational targeted radiopharmaceutical theranostic for hepatocellular carcinoma in first-in-human clinical trial - Mayo Clinic News Network

Mayo Clinic uses investigational targeted radiopharmaceutical theranostic for hepatocellular carcinoma in first-in-human clinical trial  Mayo Clinic News Network

Mayo Clinic uses investigational targeted radiopharmaceutical theranostic for hepatocellular carcinoma in first-in-human clinical trial - Mayo Clinic News Network

Click here to get full coverage on GPC3-targeted immunoPET allows for early detection of HCC: a pilot clinical study - Journal of Nuclear Medicine

GPC3-targeted immunoPET allows for early detection of HCC: a pilot clinical study  Journal of Nuclear Medicine

GPC3-targeted immunoPET allows for early detection of HCC: a pilot clinical study - Journal of Nuclear Medicine

Click here to get full coverage on Potential Rays owner considering HCC as stadium site - FOX 13 Tampa Bay

Potential Rays owner considering HCC as stadium site  FOX 13 Tampa Bay

Potential Rays owner considering HCC as stadium site - FOX 13 Tampa Bay

Click here to get full coverage on The Lancet Commission on hepatocellular carcinoma - The Lancet

The Lancet Commission on hepatocellular carcinoma  The Lancet

The Lancet Commission on hepatocellular carcinoma - The Lancet

Click here to get full coverage on TRIPLET-HCC at ESMO 2025: Adding Ipilimumab to Atezolizumab–Bevacizumab Fails to Improve Outcomes in Unresectable HCC - Oncodaily

TRIPLET-HCC at ESMO 2025: Adding Ipilimumab to Atezolizumab–Bevacizumab Fails to Improve Outcomes in Unresectable HCC  Oncodaily

TRIPLET-HCC at ESMO 2025: Adding Ipilimumab to Atezolizumab–Bevacizumab Fails to Improve Outcomes in Unresectable HCC - Oncodaily

Click here to get full coverage on SGMS2+ Macrophages Linked to Increased NR4A3hi NK Cell Infiltration in Hepatocellular Carcinoma - geneonline.com

SGMS2+ Macrophages Linked to Increased NR4A3hi NK Cell Infiltration in Hepatocellular Carcinoma  geneonline.com

SGMS2+ Macrophages Linked to Increased NR4A3hi NK Cell Infiltration in Hepatocellular Carcinoma - geneonline.com

Click here to get full coverage on On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC - OncLive

On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC  OncLive

On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC - OncLive

Click here to get full coverage on SIERRA Study in ESMO GI 2025: Efficacy of STRIDE in HCC - Oncodaily

SIERRA Study in ESMO GI 2025: Efficacy of STRIDE in HCC  Oncodaily

SIERRA Study in ESMO GI 2025: Efficacy of STRIDE in HCC - Oncodaily

Click here to get full coverage on Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC - OncLive

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC  OncLive

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC - OncLive

Click here to get full coverage on Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria - Nature

Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria  Nature

Multi-omic analysis reveals a CAF-stemness-governed classification in HCC liver transplant recipients beyond the Milan criteria - Nature

Click here to get full coverage on Irpagratinib Plus Atezolizumab Is Safe and Effective in FGF19+ Advanced HCC - OncLive

Irpagratinib Plus Atezolizumab Is Safe and Effective in FGF19+ Advanced HCC  OncLive

Irpagratinib Plus Atezolizumab Is Safe and Effective in FGF19+ Advanced HCC - OncLive

Click here to get full coverage on The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities - Springer

The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities  Springer

The immunosuppressive role of MDSCs in HCC: mechanisms and therapeutic opportunities - Springer

Click here to get full coverage on Tokio Marine HCC modernizes catastrophe modeling with Moody’s Risk Modeler™ - Moody's

Tokio Marine HCC modernizes catastrophe modeling with Moody’s Risk Modeler™  Moody's

Tokio Marine HCC modernizes catastrophe modeling with Moody’s Risk Modeler™ - Moody's

Click here to get full coverage on CircSMEK1 Suppresses HCC via the hnRNPK-IGF2-AKT Axis: A Diagnostic Biomarker and Therapeutic Target - Wiley

CircSMEK1 Suppresses HCC via the hnRNPK-IGF2-AKT Axis: A Diagnostic Biomarker and Therapeutic Target  Wiley

CircSMEK1 Suppresses HCC via the hnRNPK-IGF2-AKT Axis: A Diagnostic Biomarker and Therapeutic Target - Wiley

Click here to get full coverage on TMEM88 Controls HCC Growth via GSK-3β Pathway - Bioengineer.org

TMEM88 Controls HCC Growth via GSK-3β Pathway  Bioengineer.org

TMEM88 Controls HCC Growth via GSK-3β Pathway - Bioengineer.org

Click here to get full coverage on Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target - OncLive

Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target  OncLive

Preliminary Casdozokitug Activity in HCC Supports Further Exploration of IL-27 as a Treatment Target - OncLive

Click here to get full coverage on Hybu Cig Cymru: what’s next for Wales’ meat promotion body? - Senedd Research

Hybu Cig Cymru: what’s next for Wales’ meat promotion body?  Senedd Research

Hybu Cig Cymru: what’s next for Wales’ meat promotion body? - Senedd Research

Click here to get full coverage on HCC Share Price Today Up 6% - Equitymaster

HCC Share Price Today Up 6%  Equitymaster

HCC Share Price Today Up 6% - Equitymaster

Click here to get full coverage on FDA Approves Y-90 Resin Microspheres for Unresectable HCC - OncLive

FDA Approves Y-90 Resin Microspheres for Unresectable HCC  OncLive

FDA Approves Y-90 Resin Microspheres for Unresectable HCC - OncLive

Click here to get full coverage on Decoding the molecular and genomic landscape of hepatocellular carcinoma: biomarker discovery, classification frameworks, and therapeutic targeting | npj Gut and Liver - Nature

Decoding the molecular and genomic landscape of hepatocellular carcinoma: biomarker discovery, classification frameworks, and therapeutic targeting | npj Gut and Liver  Nature

Decoding the molecular and genomic landscape of hepatocellular carcinoma: biomarker discovery, classification frameworks, and therapeutic targeting | npj Gut and Liver - Nature

Click here to get full coverage on HCC changing name to ‘Houston City College’ in rebrand projected to cost $2.8 million - Houston Public Media

HCC changing name to ‘Houston City College’ in rebrand projected to cost $2.8 million  Houston Public Media

HCC changing name to ‘Houston City College’ in rebrand projected to cost $2.8 million - Houston Public Media

Click here to get full coverage on HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study - Nature

HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study  Nature

HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study - Nature

Click here to get full coverage on TACE Plus SBRT Effective in Large Tumors Caused by HCC - The American Journal of Managed Care® (AJMC®)

TACE Plus SBRT Effective in Large Tumors Caused by HCC  The American Journal of Managed Care® (AJMC®)

TACE Plus SBRT Effective in Large Tumors Caused by HCC - The American Journal of Managed Care® (AJMC®)

Click here to get full coverage on The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment - The Lancet

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment  The Lancet

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment - The Lancet

Click here to get full coverage on ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment - Oncodaily

ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment  Oncodaily

ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment - Oncodaily

Click here to get full coverage on A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial - Nature

A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial  Nature

A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial - Nature

Click here to get full coverage on Tegavivint Demonstrates Preliminary Antitumor Activity, Safety in Advanced HCC - OncLive

Tegavivint Demonstrates Preliminary Antitumor Activity, Safety in Advanced HCC  OncLive

Tegavivint Demonstrates Preliminary Antitumor Activity, Safety in Advanced HCC - OncLive

Click here to get full coverage on HCC name change: Houston Community College's Board of Trustees votes to rebrand the school as Houston City College - ABC13 Houston

HCC name change: Houston Community College's Board of Trustees votes to rebrand the school as Houston City College  ABC13 Houston

HCC name change: Houston Community College's Board of Trustees votes to rebrand the school as Houston City College - ABC13 Houston

Click here to get full coverage on Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC - OncLive

Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC  OncLive

Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC - OncLive

Click here to get full coverage on HCC cancels student trip to London, citing fears of Trump immigration crackdown - Houston Landing

HCC cancels student trip to London, citing fears of Trump immigration crackdown  Houston Landing

HCC cancels student trip to London, citing fears of Trump immigration crackdown - Houston Landing

Click here to get full coverage on Advanced HCC: Which First-line Treatment Is Best? - Medscape

Advanced HCC: Which First-line Treatment Is Best?  Medscape

Advanced HCC: Which First-line Treatment Is Best? - Medscape

Click here to get full coverage on AI enhanced diagnostic accuracy and workload reduction in hepatocellular carcinoma screening | npj Digital Medicine - Nature

AI enhanced diagnostic accuracy and workload reduction in hepatocellular carcinoma screening | npj Digital Medicine  Nature

AI enhanced diagnostic accuracy and workload reduction in hepatocellular carcinoma screening | npj Digital Medicine - Nature

Click here to get full coverage on Help wanted: Many HCC international students scramble for work, but few get it - Houston Landing

Help wanted: Many HCC international students scramble for work, but few get it  Houston Landing

Help wanted: Many HCC international students scramble for work, but few get it - Houston Landing

Click here to get full coverage on Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy - Nature

Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy  Nature

Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy - Nature

Click here to get full coverage on Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors - Nature

Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors  Nature

Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors - Nature

Click here to get full coverage on Past, Present, and Couture: Asian Fashion From the HCC Archive - Asia Society

Past, Present, and Couture: Asian Fashion From the HCC Archive  Asia Society

Past, Present, and Couture: Asian Fashion From the HCC Archive - Asia Society

Click here to get full coverage on TACE Plus Drug Combination Effective in Liver Cancer - National Cancer Institute (.gov)

TACE Plus Drug Combination Effective in Liver Cancer  National Cancer Institute (.gov)

TACE Plus Drug Combination Effective in Liver Cancer - National Cancer Institute (.gov)

Click here to get full coverage on HCC asked 1,800 people about changing the community college’s name. Here’s what they said. - Houston Landing

HCC asked 1,800 people about changing the community college’s name. Here’s what they said.  Houston Landing

HCC asked 1,800 people about changing the community college’s name. Here’s what they said. - Houston Landing

Click here to get full coverage on HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA - The American Journal of Managed Care® (AJMC®)

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA  The American Journal of Managed Care® (AJMC®)

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA - The American Journal of Managed Care® (AJMC®)

Click here to get full coverage on Elizabeth Geary named CEO of Tokio Marine HCC’s North America P&C division - Insurance Business

Elizabeth Geary named CEO of Tokio Marine HCC’s North America P&C division  Insurance Business

Elizabeth Geary named CEO of Tokio Marine HCC’s North America P&C division - Insurance Business

Click here to get full coverage on Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation - Nature

Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation  Nature

Disrupting bile acid metabolism by suppressing Fxr causes hepatocellular carcinoma induced by YAP activation - Nature

Click here to get full coverage on UH, HCC restart faculty advisory groups with more guardrails - Houston Chronicle

UH, HCC restart faculty advisory groups with more guardrails  Houston Chronicle

UH, HCC restart faculty advisory groups with more guardrails - Houston Chronicle

Click here to get full coverage on APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC - Oncodaily

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC  Oncodaily

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC - Oncodaily

Click here to get full coverage on Transcription factor JUNB is required for transformation of EpCAM-positive hepatocellular carcinoma (HCC) cells into CD90-positive HCC cells in vitro - Nature

Transcription factor JUNB is required for transformation of EpCAM-positive hepatocellular carcinoma (HCC) cells into CD90-positive HCC cells in vitro  Nature

Transcription factor JUNB is required for transformation of EpCAM-positive hepatocellular carcinoma (HCC) cells into CD90-positive HCC cells in vitro - Nature

Click here to get full coverage on 'Houston Community College' no more | HCC just announced a new name - KHOU

'Houston Community College' no more | HCC just announced a new name  KHOU

'Houston Community College' no more | HCC just announced a new name - KHOU

Click here to get full coverage on Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma - Nature

Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma  Nature

Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma - Nature

Click here to get full coverage on Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study - Nature

Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study  Nature

Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study - Nature

Click here to get full coverage on NMPA Approves sNDA for Toripalimab Plus Bevacizumab in Advanced HCC - OncLive

NMPA Approves sNDA for Toripalimab Plus Bevacizumab in Advanced HCC  OncLive

NMPA Approves sNDA for Toripalimab Plus Bevacizumab in Advanced HCC - OncLive

Click here to get full coverage on Characteristics and Survival Outcomes of Hepatocellular Carcinoma After the Fontan Operation - ScienceDirect.com

Characteristics and Survival Outcomes of Hepatocellular Carcinoma After the Fontan Operation  ScienceDirect.com

Characteristics and Survival Outcomes of Hepatocellular Carcinoma After the Fontan Operation - ScienceDirect.com

Click here to get full coverage on Cooperative targeting of NF-κB enhances ferroptosis-driven HCC therapy with Alisertib and Donafenib - Frontiers

Cooperative targeting of NF-κB enhances ferroptosis-driven HCC therapy with Alisertib and Donafenib  Frontiers

Cooperative targeting of NF-κB enhances ferroptosis-driven HCC therapy with Alisertib and Donafenib - Frontiers

Click here to get full coverage on Targeting TFAM downregulation mediated mtDNA-NLRP3 pathway suppresses TAM infiltration and HCC progression - Nature

Targeting TFAM downregulation mediated mtDNA-NLRP3 pathway suppresses TAM infiltration and HCC progression  Nature

Targeting TFAM downregulation mediated mtDNA-NLRP3 pathway suppresses TAM infiltration and HCC progression - Nature

Click here to get full coverage on Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians - Wiley

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians  Wiley

Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians - Wiley

Click here to get full coverage on Green jackfruit flour ameliorates MASH and development of HCC via the AMPK and MAPK signaling pathways in experimental model systems - Nature

Green jackfruit flour ameliorates MASH and development of HCC via the AMPK and MAPK signaling pathways in experimental model systems  Nature

Green jackfruit flour ameliorates MASH and development of HCC via the AMPK and MAPK signaling pathways in experimental model systems - Nature

Click here to get full coverage on Spatial immune scoring system predicts hepatocellular carcinoma recurrence - Nature

Spatial immune scoring system predicts hepatocellular carcinoma recurrence  Nature

Spatial immune scoring system predicts hepatocellular carcinoma recurrence - Nature

Click here to get full coverage on Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial - The Lancet

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial  The Lancet

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial - The Lancet

Click here to get full coverage on The epigenetic basis of hepatocellular carcinoma – mechanisms and potential directions for biomarkers and therapeutics | British Journal of Cancer - Nature

The epigenetic basis of hepatocellular carcinoma – mechanisms and potential directions for biomarkers and therapeutics | British Journal of Cancer  Nature

The epigenetic basis of hepatocellular carcinoma – mechanisms and potential directions for biomarkers and therapeutics | British Journal of Cancer - Nature

HCC

Price Chart

Key Statistics

Technicals

About HCC

Latest News

Early voting opens in Houston’s At-Large 4 and HCC District II runoffs - Houston Chronicle

HCC shares jump over 14% as board approves Rs 1,000 crore rights issue; record date & other details - MSN

HCC ₹1,000 Crore Rights Issue: Check entitlement, record date, other details here - CNBC TV18

Advanced Charts

Top Gainers

Top Losers